Lisata Therapeutics ( (LSTA) ) has provided an announcement.
On February 27, 2025, Lisata Therapeutics reported its financial results for the fiscal year ending December 31, 2024, and provided a business update. The company highlighted promising preliminary data from its Phase 2b ASCEND trial for pancreatic cancer and announced the completion of enrollment in Qilu’s Phase 2 trial for certepetide. Lisata is advancing its development portfolio with multiple milestones expected over the next year, supported by a cash runway extending into the second quarter of 2026. The company is conducting several clinical trials globally, focusing on the efficacy of certepetide in combination with standard-of-care treatments for various cancers, including pancreatic, cholangiocarcinoma, and glioblastoma.
More about Lisata Therapeutics
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases. The company’s primary product candidate, certepetide, is being explored for its potential in treating various solid tumors and non-cancerous conditions.
YTD Price Performance: -33.05%
Average Trading Volume: 44,826
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $20.06M
Find detailed analytics on LSTA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com